Atlas Trials

Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)

Clinical trial NCT01932762 · COMPLETED

Trial details

NCT number
NCT01932762
Sponsor
Merck Sharp & Dohme LLC
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Hepatitis C
Start date
2013-10-01
Primary completion
2014-12-04
Enrollment
98

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.